Drugs /

necitumumab

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
necitumumab
Trade Name(s):
Portrazza
NCI Definition [1]:
A fully human IgG1 monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Necitumumab binds to and blocks the ligand binding site of EGFR, thereby preventing the activation and subsequent dimerization of the receptor. This may lead to an inhibition of EGFR-dependent downstream pathways and so inhibition of EGFR-dependent tumor cell proliferation and metastasis. EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of various tumor cell types.

Clinical Trials

View Clinical Trials for necitumumab

Necitumumab has been investigated in 5 clinical trials, of which 4 are open and 1 is closed. Of the trials investigating necitumumab, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open).

EGFR A763_Y764insFQEA, EGFR Exon 19 Deletion, and EGFR Exon 19 Insertion are the most frequent biomarker inclusion criteria for necitumumab clinical trials.

Non-small cell lung carcinoma, lung adenocarcinoma, and squamous cell lung carcinoma are the most common diseases being investigated in necitumumab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Necitumumab
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Necitumumab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating necitumumab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
imc-11f8, necitumumab (substance), anti-egfr monoclonal antibody imc-11f8, imc-11f8 monoclonal antibody, immunoglobulin g1, anti-(human epidermal growth factor receptor (receptor tyrosine-protein kinase erbb-1, ec 2.7.10.1)); human monoclonal imc-11f8 gamma1 heavy chain (224-214')-disulfide with human monoclonal imc-11f8 kappa light chain, dimer (230- 230'':233-233'')-bisdisulfide, anti-epidermal growth factor receptor monoclonal antibody imc-11f8, necitumumab, necitumumab, Portrazza
Drug Categories [2]:
Therapeutic antibodies
Drug Target(s) [2]:
EGFR
NCIT ID [1]:
C88281
SNOMED ID [1]:
R-FF7E0

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.